CD19 and hematopoietic and lymphoid system neoplasm: The first CAR NK clinical trials began in 2016, and currently there are 32 CAR NK cell therapies in clinical trials, with many of them aimed at targeting blood cancers through BCMA and CD19 antigen-targeting [109,115,116].